Cost-effectiveness analysis of telemonitoring versus usual care in patients with heart failure: the TEHAF-study

被引:34
|
作者
Boyne, Josiane J. J. [1 ]
Van Asselt, Antoinette D. I. [1 ]
Gorgels, Anton P. M. [2 ]
Steuten, Lotte M. G. [3 ]
De Weerd, Gerjan [4 ]
Kragten, Johannes [5 ]
Vrijhoef, Hubertus J. M. [6 ,7 ]
机构
[1] Maastricht Univ, Med Ctr, Dept Patient & Care, Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Cardiol, Maastricht, Netherlands
[3] Univ Twente, NL-7500 AE Enschede, Netherlands
[4] Orbis Med & Care Concern, Dept Cardiol, Sittard, Netherlands
[5] Atrium Med Concern, Dept Cardiol, Heerlen, Netherlands
[6] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore
[7] Tilburg Univ, Sci Ctr Care & Welf, NL-5000 LE Tilburg, Netherlands
关键词
HEALTH; TELEMEDICINE; OUTCOMES;
D O I
10.1177/1357633X13495478
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
We examined the incremental cost-effectiveness of telemonitoring (TM) versus usual care (UC) in patients with congestive heart failure (CHF). In one university and two general hospitals, 382 patients were randomised to usual care or telemonitoring and followed for 1 year. Hospital-related and home costs were estimated, based on resource use multiplied by the appropriate unit prices. Effectiveness was expressed as QALYs gained. Information was gathered, using 3 monthly costs diaries and questionnaires. The mean age of the patients was 71 years (range 32-93), 59% were male and 64% lived with a partner. Health related quality of life improved by 0.07 points for the usual care and 0.1 points for the telemonitoring group, but the difference between groups was not significant. There were no significant differences in annual costs per patient between groups. At a threshold of (sic)50,000 the probability of telemonitoring being cost-effective was 48%. The cost effectiveness analysis showed a high level of decision uncertainty, probably caused by the divergence between the participating institutions. It is therefore premature to draw an unambiguous conclusion regarding cost-effectiveness for the whole group.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 50 条
  • [31] Telemonitoring versus usual care in continuous positive airway pressure users: cost analysis
    Ekroos, Heikki
    Karvonen, Tanja
    Hahl, Jarmo
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [32] COST-EFFECTIVENESS ANALYSIS OF MYOSTRAIN IN THE EARLY DETECTION OF HEART FAILURE PATIENTS
    Stojanovic, I
    Schneider, J. E.
    [J]. VALUE IN HEALTH, 2018, 21 : S216 - S216
  • [33] COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN TREATMENT OF PATIENTS WITH HEART FAILURE IN IRAN
    Taheri, Saeed
    Heidari, Elham
    Aivazi, Mohammad Ali
    Shams-Beyranvand, Mehran
    Varmaghani, Mehdi
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2018, 34 (06) : 576 - 583
  • [34] Cost-effectiveness analysis of pharmacist interventions in patients with heart failure in Thailand
    Arunmanakul, Poukwan
    Chaiyakunapruk, Nathorn
    Phrommintikul, Arintaya
    Ruengorn, Chidchanok
    Permsuwan, Unchalee
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2022, 62 (01) : 71 - 78
  • [35] Cost-effectiveness of a telemonitoring programme in patients with cardiovascular diseases compared with standard of care
    Ziegler, Andreas
    Oner, Alper
    Quadflieg, Gisela
    Betschart, Raphael O.
    Thiery, Alexandre
    Babel, Hugo
    Mwambi, Henry G.
    Neumeyer, Henriette
    Mackschin, Steffen
    Hintz, Sissy
    Mann, Miriam
    Dittrich, Hermann
    Schmidt, Christian
    [J]. HEART, 2023, 109 (21) : 1617 - 1623
  • [36] Cost-effectiveness of spironolactone in patients with severe heart failure
    L Tilson
    B McGowan
    M Ryan
    M Barry
    [J]. Irish Journal of Medical Science, 2003, 172 : 70 - 72
  • [37] Cost-effectiveness of Levosimendan in Patients With Acute Heart Failure
    Fedele, Francesco
    D'Ambrosi, Alessandra
    Bruno, Noemi
    Caira, Carmen
    Brasolin, Bruno
    Mancone, Massimo
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2011, 58 (04) : 363 - 366
  • [38] Cost-effectiveness of spironolactone in patients with severe heart failure
    Tilson, L
    McGowan, B
    Ryan, M
    Barry, M
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2003, 172 (02) : 70 - 72
  • [39] COST-EFFECTIVENESS OF RULING OUT DEEP VENOUS THROMBOSIS IN PRIMARY CARE VERSUS CARE AS USUAL
    Ten Cate-Hoek, A. J.
    Toll, D. B.
    van der Velde, E. F.
    Buller, H.
    Hoes, A. W.
    Moons, K. G.
    Oudega, R.
    Prins, M. H.
    Stoffers, H. E.
    van Weert, H. C.
    Joore, M. A.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A396 - A396
  • [40] Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual
    ten Cate-Hoek, A. J.
    Toll, D. B.
    Buller, H. R.
    Hoes, A. W.
    Moons, K. G. M.
    Oudega, R.
    Stoffers, H. E. J. H.
    van der Velde, E. F.
    van Weert, H. C. P. M.
    Prins, H.
    Joore, M. A.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (12) : 2042 - 2049